Analyst Price Target is $3.00
▲ +489.39% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Rockwell Medical in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 489.39% upside from the last price of $0.51.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Rockwell Medical. This Buy consensus rating has held steady for over two years.
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.